Ohio Health Research Institute
Ohio Health Research Institute
Columbus, Ohio, United States18 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07214779 | |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-10-07 | NCT05243797 | |
| Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing | Arrhythmias, Cardiac, Cardiac Conduction System Disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tachycardia, cardiovascular disorder, heart disorder, ventricular tachycardia | Active, not recruiting | Not applicable | 2026-10-02 | NCT04798768 | |
| A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis | Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, proteostasis deficiencies | Active, not recruiting | Phase 2 | 2026-09-25 | NCT05250973 | |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 3 | 2026-09-09 | NCT05633654 | |
| Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | Relapsing Multiple Sclerosis | Recruiting | Phase 3 | 2026-08-26 | NCT06846281 | |
| GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections | Acute Aortic Syndrome, Aneurysm, Aortic Dissection, Dissection, Blood Vessel, aortic disorder, cardiovascular disorder, vascular disorder | Recruiting | Not applicable | 2026-08-11 | NCT06827990 | |
| Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 3 | 2026-07-29 | NCT06486441 | |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2026-07-02 | NCT06578247 | |
| Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS | Relapsing Multiple Sclerosis | Active, not recruiting | Phase 3 | 2026-05-27 | NCT03650114 | |
| Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, atrial septal defect, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, congenital heart disease, heart disorder, heart septal defect, nervous system disorder, patent foramen ovale, stroke disorder, vascular disorder | Active, not recruiting | Not applicable | 2026-05-22 | NCT05069558 | |
| Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder, paroxysmal atrial fibrillation, persistent atrial fibrillation | Active, not recruiting | Phase 4 | 2026-04-14 | NCT06765356 | |
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, amyloidosis, cardiomyopathy, cardiovascular disorder, familial amyloid neuropathy, heart disorder, hereditary amyloidosis, hereditary disease, inborn errors of metabolism, metabolic disease, proteostasis deficiencies | Recruiting | Phase 3 | 2026-03-27 | NCT06128629 | |
| Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms | Aneurysm, abdominal aortic aneurysm, aortic aneurysm, aortic disorder, cardiovascular disorder, vascular disorder | Active, not recruiting | Not applicable | 2025-08-13 | NCT02489539 | |
| A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Active, not recruiting | Phase 3 | 2025-08-07 | NCT05210790 | |
| PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Not applicable | 2025-06-13 | NCT06445608 | |
| TRILUMINATE Pivotal Trial | cardiovascular disorder, heart disorder, heart valve disorder, tricuspid valve insufficiency | Active, not recruiting | Not applicable | 2024-12-19 | NCT03904147 | |
| The JenaValve ALIGN-AR Pivotal Trial | aortic valve disorder, aortic valve insufficiency, cardiovascular disorder, heart disorder, heart valve disorder | Active, not recruiting | Not applicable | 2022-09-13 | NCT04415047 |